Economists can’t agree if the U.S. is headed for a “soft landing” recession, a hard landing, or no recession at...
Originally published on HIT Consultant by Dr. Minh Huynh, Medical Director at NantHealth Eliminating healthcare inequities requires addressing the underlying social...
While spending on oncology drugs in the U.S. is anticipated to reach $125 billion by 2027, overall drug savings of...
It is time to use our available tools to create equitable healthcare solutions. Originally published on Benefits Pro With 2023...
As the biopharmaceutical industry evolves rapidly, biosimilar products are reshaping the autoimmune treatment paradigm. This comprehensive eBook explores the role...
NantHealth explores the impact of new biosimilar drugs for autoimmune treatment. We will discuss how payers can prepare for the...
The 2020 San Antonio Breast Cancer Symposium (SABCS) was held from December 8 to December 12, 2020. During the virtual...
Dr. William Flood, Chief Medical Officer for Eviti at NantHealth, discusses new significant findings from Eviti Connect, presented at the...
Here are the top 5 biosimilar articles for the week of December 14, 2020.
Investigators studying trastuzumab biosimilar savings and use rates across different disease settings in human epidermal growth factor receptor 2 (HER2)-positive...
NantHealth’s study data shows: Adoption of trastuzumab biosimilars in treatment of HER2-positive breast cancer is significant; does not appear to...